Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22281038 | 0.86 | MEN1 (0.36) | SMN1; SMN2L3MBTL3L3MBTL1HRH3OPRL1 | |
| SCHEMBL25066719 | 0.86 | HRH3 (0.42) | HRH3TP53 | |
| SCHEMBL23219677 | 0.84 | SMN1; SMN2 (0.33) | SMN1; SMN2HRH3ALDH1A1LMNA | |
| SCHEMBL23784287 | 0.81 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1HRH3OPRL1TP53 | |
| SCHEMBL8255414 | 0.81 | HRH3 (0.46) | SMN1; SMN2L3MBTL3L3MBTL1HRH3OPRL1 | |
| SCHEMBL23108665 | 0.80 | KMT2A (0.42) | SMN1; SMN2L3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL21564194 | 0.80 | KMT2A (0.42) | SMN1; SMN2L3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL643674 | 0.80 | KMT2A (0.42) | SMN1; SMN2L3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL22456358 | 0.80 | TSHR (0.40) | L3MBTL1HRH3OPRL1TP53 | |
| SCHEMBL3773717 | 0.80 | KDM4E (0.57) | L3MBTL3L3MBTL1HRH3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20210009613-A1 | ARYLPHOSPHINE OXIDES FOR INHIBITING KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-01-14 | — | — | US | disclosed |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009613-A1 | ARYLPHOSPHINE OXIDES FOR INHIBITING KINASE ACTIVITY | ALK, SKP1, ROS1 | SMN1; SMN2 1049/4885L3MBTL3 2131/4885L3MBTL1 1240/4885 |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | SMN1; SMN2 2349/4885L3MBTL3 813/4885L3MBTL1 751/4885 |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | SMN1; SMN2 3216/4885L3MBTL3 4536/4885L3MBTL1 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.